Carealytix is a digital health company transforming chronic care through user-centric technology. They develop digital products and platforms aimed at providing personalized care solutions for people living with chronic conditions, with a strong focus on kidney care.

They partner with healthcare providers, payers, researchers, and industry to achieve positive health outcomes by creating scalable, data-driven solutions grounded in medicine and intuitive to use.

Carealytix offers a comprehensive digital care platform designed to redefine the benchmark in kidney care. Their platform supports patient education, health tracking, remote monitoring, clinical trial support, and data sharing with healthcare providers.

Their flagship products include Mizu, a personal companion app for chronic kidney disease (CKD) patients with over 25,000 registered users, and Kidney+, a telecoaching hybrid care program specializing in supporting patients with diagnosed kidney disease between regular doctor's visits.

Regulatory compliance is integral to their operations, with certifications including CE marking as software-as-medical-device under EU-MDR, ISO-13485 certification, and full GDPR compliance for health data processing.

Carealytix aims to eliminate gaps in healthcare by streamlining patient-physician interaction, enhancing clinical workflow efficiency, and automating routine tasks to allow healthcare teams to focus more on patient care.

They emphasize patient engagement, health research innovation, data science, real-world evidence (RWE) generation, and integrated interdisciplinary care to address complex chronic conditions and comorbidities.